Humira Revenue Up 9.6% In U.S., But Down Abroad Due To Biosimilars

By John Wilkerson / November 7, 2019 at 12:33 PM
Humira revenues fell 33.5% internationally in the third quarter of this year due to biosimilar competition, according to AbbVie, while revenues increased 9.6% in the United States, where there is no biosimilar competition until 2023. Humira tops the list of seven drugs with the biggest unsupported price increases, according to the Institute for Clinical and Economic Review . Humira is one of the high-profile cases of patent settlements that delay generic or biosimilar competition, though AbbVie says the settlements are...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.